Advertisement
Vaccine scandal in China
MoneyStock Talk

China’s stocks regulator sets legal framework to expel firms that pollute, or make fake vaccines

Companies involved in fraud, disclosure violations or whose actions harm public health, national or ecological security, will be expelled from the stock market

Reading Time:2 minutes
Why you can trust SCMP
A container used for clinical waste is seen at a private clinic that performs vaccinations in Hong Kong on July 24, 2018. Hong Kong clinics said they have seen a surge in demand for children's vaccines on July 24 after a safety scandal in mainland China. Photo: AFP
Zheng Yangpengin Beijing

China’s securities regulator, responding to public uproar over a vaccines scandal, has strengthened the expulsion rules on the country’s equity exchanges, laying the groundwork for kicking out culpable producers from the capital market.

Stock exchanges should take the lead to delist, or suspend any listed company that’s involved in fraud, any violations of disclosure rules, or whose action “threatened public health, national or ecological security,” the China Securities Regulatory Commission said, citing revised listing regulations released on late Friday night.

The revised rules give teeth to a regulatory framework that has otherwise stood powerlessly by while dozens of companies continued to raise funds through Asia’s biggest capital market, even after they’ve been held responsible for pollution, corporate malfeasance or producing substandard foodstuff and medicine.

Advertisement

Embattled Chinese vaccine maker Changsheng Bio-technology risks delisting  

“This is significant change,” said Xu Feng, a senior partner at Shanghai Trend Law Firm, according to the China Economics Weekly. “There will be additional delistings because of the added criteria.”

Advertisement

China has been roiled in recent weeks by revelations that several vaccine producers had falsified their inspection and manufacturing records, releasing hundreds of thousands of doses of ineffective or substandard medicine into the market. President Xi Jinping ordered a thorough investigation, and Premier Li Keqiang dispatched a task force to crack down on substandard producers nationwide.

Shenwan Hongyuan Medical and Biotech Index, which tracks the performance of 283 companies in the health care and pharmaceuticals sector, lost 2.9 per cent this week, the worst performing sector on the stock market.

Advertisement
Select Voice
Choose your listening speed
Get through articles 2x faster
1.25x
250 WPM
Slow
Average
Fast
1.25x